Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long-term Follow-up of Patients Participating in RACE: the Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients

NCT05049668 is registered in ClinicalTrials.gov with European Society for Blood and Marrow Transplantation as lead sponsor.

NCT NCT05049668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05049668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long-term Follow-up of Patients Participating in RACE: the Prospective Randomized Multicenter Study Comparing Horse Antithymocyte Globuline (hATG) + Cyclosporine A (CsA) With or Without Eltrombopag as Front-line Therapy for Severe Aplastic Anemia Patients
Lead sponsor
European Society for Blood and Marrow Transplantation
Phase
Observational
Overall status
Enrolling by invitation
Start date
October 31, 2021
Completion date
December 31, 2034
Enrollment
197 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

severe aplastic anemia